Reflections on Including Patients in a Randomized Placebo-Controlled Multicentre Trial in the Dying Phase – the SILENCE Study

• Published in: Journal of pain and symptom management Vol. 63; no. 5; pp. e545 - e552
• Main Authors: van Esch, Harriëtte J., Prins, Sanne D., van de Vathorst, Suzanne, van der Rijt, Carin C.D., van der Heide, Agnes, van Zuylen, Lia
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2022; Elsevier Limited
• Subjects: Butylscopolammonium Bromide; Clinical trials; Death; Death & dying; Deterioration; Drugs; Efficacy; End of life; End of life decisions; Ethics; Health care; Hospice Care; Hospices; Hospitalization; Humans; Informed Consent; Inpatient care; Medical personnel; Multicenter studies; Multicenter Studies as Topic; Palliative care; Participation; Patients; Randomized Controlled Trials as Topic; RCT; Recruitment; Vulnerability; Ethics; Participation; RCT; Research; End of life; Recruitment
• ISSN: 0885-3924; 1873-6513
• DOI: 10.1016/j.jpainsymman.2021.12.018

A need exists for studies investigating symptom relief at the end of life. Randomised controlled trials (RCTs) are the gold standard for demonstrating efficacy of medication, but they are difficult to perform at the end of life due to barriers such as the vulnerability of patients, and gatekeeping by healthcare professionals. We analyzed and reflected on recruitment, participation, and strategies used in an RCT at the end of life. The SILENCE study, performed in six inpatient hospice facilities, was a placebo-controlled trial to study the effect of ScopolamIne butyLbromidE giveN prophylactiCally for dEath rattle in dying patients. We addressed patients’ vulnerability by using an advance consent procedure, and potential gatekeeping by extensive training of health care professionals and the appointment of hospice doctors as daily responsible researchers. In almost three years, 1097 patients were admitted of whom 626 were eligible at first assessment. Of these, 119 (19%) dropped out because of physical deterioration before they could be informed about the study (44) or sign informed consent (75). Twenty-five (4%) patients were not asked to participate. In 24 cases (4%), relatives advised against the patient participating. Overall, 229 patients (37%) gave informed consent to participate. The vulnerability of patients was the most important barrier in this medication study at the end of life. Gatekeeping by HCPs and relatives occurred in a small number of patients. The robust design and applied strategies to facilitate patient recruitment in this study resulted in a successful study with sufficient participants.